Highly complementary spine and orthopedics portfolios One of the industry’s broadest biologics and regenerative technology offerings Differentiated and synergistic enabling technologies Meaningful cross-selling revenue synergies and cost savings
Opportunities are available for several areas of the company in different regions of the United States and Canada To learn more about career opportunities including internship and trainee positions, visit our webpage on bunge.com. ST. LOUIS--(BUSINES
-- Cybin and The Chopra Foundation continue to work together to advance the research and education of psychedelic-based therapeutics as a new paradigm for the treatment of mental health -- TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CY
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and oth
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce that the Company’s
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nutrien Ltd (TSX and NYSE: NTR) announced today plans to release third quarter earnings results on Wednesday, November 2, 2022, after market close. Nutrien will host a conference call the following day, Thursday,
VANCOUVER, British Columbia--(BUSINESS WIRE)--Life Sciences BC today announced the companies and mentors participating in its 2023 Investor Readiness Program (IRP). Through an intensive six-month program, 10 early-stage small and mid-size enterprises (SME
Fully integrated companies streamline access to genetically modified stem cells for clinical development SEATTLE--(BUSINESS WIRE)--#CellTherapy--Today, Pluristyx, panCELLa, and Implant Therapeutics management are excited to announce their corporate merge
Clinical Study demonstrated dual benefit mode of action of Thykamine™ in mild-to-moderate Atopic Dermatitis: Statistically significant effect on Atopic Dermatitis evaluated by measure of IGA, BSA and POEM Statistically beneficial effect on Pruriti
VANCOUVER, British Columbia--(BUSINESS WIRE)--EverGen Infrastructure Corp. (“EverGen” or the “Company”) (TSXV: EVGN) (OTCQX: EVGIF), is pleased to announce the appointment of Sean Hennessy as Chief Financial Officer (“CFO”), effective immediat
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.